Education
About Us
Working with TipRanks
Follow Us
Xoma Corp (XOMA)
NASDAQ:XOMA
XOMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$21.27 - $35.00
Previous CloseN/A
Volume8.24K
Average Volume (3M)50.03K
Market Cap
$277.13M
Enterprise Value$286.21M
Total Cash (Recent Filing)$45.78M
Total Debt (Recent Filing)$22.48M
Price to Earnings (P/E)―
Beta0.60
Next Earnings
Mar 06, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.48
Shares Outstanding11,782,723
10 Day Avg. Volume29,833
30 Day Avg. Volume50,028
Standard Deviation0.16
R-Squared0.09
Alpha0.00381
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.82
Price to Cash Flow (P/CF)-8.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.03
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit74.13
Enterprise Value/Ebitda-6.97
Forecast
1Y Price Target
$104.00Price Target Upside358.15% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Xoma News
PremiumCompany Announcements
XOMA Royalty’s Third Quarter 2024 Financial Insights
PremiumPre-Earnings
Xoma Corp. (XOMA) Q3 Earnings Cheat Sheet
---
Bulls Say, Bears Say
Bulls Say
Market GrowthVabysmo is winning market share and could continue to exceed consensus expectations.
Product ApprovalMiplyffa was recently approved for the treatment of Niemann-Pick Type C disease, with XOMA entitled to a mid-single digit royalty.
Bears Say
Financial ProjectionsThe price target has been reduced to $104 from $123, primarily based on the removal of iscalimab from projections.
---
Ownership Overview
1.53% Insiders
12.98% Mutual Funds
40.03% Other Institutional Investors
39.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
XOMA FAQ
What was Xoma Corp’s price range in the past 12 months?
Xoma Corp lowest stock price was $21.27 and its highest was $35.00 in the past 12 months.
What is Xoma Corp’s market cap?
Xoma Corp’s market cap is $277.13M.
When is Xoma Corp’s upcoming earnings report date?
Xoma Corp’s upcoming earnings report date is Mar 06, 2025 which is in 3 days.
How were Xoma Corp’s earnings last quarter?
Xoma Corp released its earnings results on Nov 07, 2024. The company reported -$1.59 earnings per share for the quarter, missing the consensus estimate of -$0.437 by -$1.153.
Is Xoma Corp overvalued?
According to Wall Street analysts Xoma Corp’s price is currently Undervalued.
Does Xoma Corp pay dividends?
Xoma Corp does not currently pay dividends.
What is Xoma Corp’s EPS estimate?
Xoma Corp’s EPS estimate is -0.29.
How many shares outstanding does Xoma Corp have?
Xoma Corp has 11,782,723 shares outstanding.
What happened to Xoma Corp’s price movement after its last earnings report?
Xoma Corp reported an EPS of -$1.59 in its last earnings report, missing expectations of -$0.437. Following the earnings report the stock price went down -6.962%.
Which hedge fund is a major shareholder of Xoma Corp?
Currently, no hedge funds are holding shares in XOMA
---
Xoma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$104.00 (358.15% Upside)
$104.00 (358.15% Upside)
Hedge Fund Trend
Increased
By 60.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-9.01%
12-Months-Change
Fundamentals
Return on Equity
-31.41%
Trailing 12-Months
Asset Growth
79.98%
Trailing 12-Months
Company Description
Xoma Corp
XOMA Corp. engages in the discovery and development of innovative therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.
---
XOMA Stock 12 Month Forecast
Average Price Target
$104.00
▲(358.15% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Corcept Therapeutics
―
Madrigal Pharmaceuticals
―
GlycoMimetics
―
AnaptysBio
―
Best Analysts Covering XOMA
1 Year
1 Year Success Rate
5/16 ratings generated profit
1 Year Average Return
+5.17%
reiterated a buy rating 28 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 31.25% of your transactions generating a profit, with an average return of +5.17% per trade.
---